GlaxoSmithKline’s 1Q17 Estimates: Vaccines Business
The Novartis acquisition has improved sales for GSK's Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe.
The Novartis acquisition has improved sales for GSK's Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe.